John Overdeck’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

John Overdeck’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$1.2M	–	3776
2020 Q1	$1.2M	Sell	25,000 -14,589	-37%	-$679K	0.01%	1290
2019 Q4	$1.86M	Sell	39,589 -65,928	-62%	-$2.91M	0.01%	1647
2019 Q3	$2.5M	Buy	105,517 +64,753	+159%	+$1.92M	0.01%	1257
2019 Q2	$1.23M	Sell	40,764 -168,296	-81%	-$3.86M	﹤0.01%	1775
2019 Q1	$4.68M	Buy	+209,060	New	+$4.49M	0.02%	998
2018 Q3	–	Sell	-15,900	Closed	-$158K	–	3789
2018 Q2	$158K	Sell	15,900 -65,789	-81%	-$454K	﹤0.01%	3169
2018 Q1	$434K	Buy	81,689 +62,337	+322%	+$446K	﹤0.01%	2554
2017 Q4	$164K	Buy	+19,352	New	+$238K	﹤0.01%	2959

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

John Overdeck's RARX Position: Q2 2020 in Review

John Overdeck sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 25,000 shares — an estimated $1.2M sold.

John Overdeck first reported a position in RARX in Q4 2017 and held it in 8 quarters. The position peaked at $4.68M in Q1 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

John Overdeck reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
John Overdeck sold 25,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.2M.
John Overdeck first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
John Overdeck's Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.68M in Q1 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Two Sigma Investments's 13F filing for Q2 2020, filed 14 Aug 2020.